Intuitive Surgical (Nasdaq: ISRG): Proof That Robots Can Be a Great Business
While humanoid developers debate what "deployment" even means, Intuitive Surgical has been running a genuinely mature robotics deployment business for two decades: 11,710 da Vinci surgical systems installed worldwide, doing paid, productive work every single day, generating 85% of revenue from recurring instruments, accessories and services rather than one-time hardware sales.
Who they are
Intuitive Surgical pioneered robotic-assisted surgery and remains the category's dominant player through its da Vinci multi-arm surgical platform and its Ion endoluminal system for lung biopsy. Founded decades before "physical AI" became an investment theme, the company has already solved, at genuine commercial scale, the exact problem every humanoid developer profiled elsewhere in this chain is still working toward: getting a robot to perform complex, high-stakes physical tasks reliably enough that customers pay for it repeatedly.
Leadership transitioned in 2025 after fifteen years under CEO Gary Guthart, who moved to executive chair in July 2025 as President Dave Rosa, a 29-year company veteran who joined as its ninth employee in 1996, was promoted to CEO. Guthart remains with the company in a senior advisory capacity, described in his own words as a "purposeful change" following disciplined succession planning intended to preserve the company's mission and culture through the leadership shift.
What they do
The core business model is instructive for the entire industry this chain describes: Intuitive doesn't primarily sell surgical robots as one-time capital purchases. It places systems — often at a loss-leader or thin margin on the hardware itself — and then generates the bulk of its revenue from the recurring instruments and accessories consumed with every single procedure, plus ongoing service contracts. That structure means Intuitive's financial health tracks procedure volume growth far more closely than new system sales, a fundamentally different and more durable economic model than a one-time robot sale.
Q2 2026 system placements reflected a generational product transition: 468 da Vinci systems placed in the quarter, of which 246 were the newer da Vinci 5 platform, up from 180 a year earlier — meaning roughly half of all new placements are already the latest generation. Management noted that approximately half of U.S. placements in the quarter were trade-ins from existing customers upgrading rather than net-new installed base expansion, an important distinction for reading headline placement numbers: da Vinci 5 utilisation runs roughly 11% higher than its predecessor, so trade-ins still expand procedure capacity even without adding a net-new hospital customer.
International growth remained strong across the board, with da Vinci procedure growth of roughly 20% internationally, split evenly between Europe and Asia, and slightly higher in the rest of world, indicating the recurring-procedure business model is scaling globally rather than being confined to its original U.S. base.
How they make money
Q2 2026 revenue reached $2.89 billion, up 19% year over year, driven by continued procedure volume growth, higher da Vinci system leasing revenue, and installed base expansion. Worldwide procedures across da Vinci and Ion combined grew approximately 16%, with da Vinci procedures up about 15% and Ion procedures up a striking 36%, reflecting genuinely strong adoption of the newer bronchoscopy platform on top of the mature core da Vinci business.
Full-year 2026 guidance calls for worldwide da Vinci procedure growth of approximately 13.5% to 15.5%, unchanged even after the Q2 beat, with management flagging some U.S. market moderation: procedures can be deferred, and changes to ACA premium subsidies plus continued pressure on bariatric procedures specifically were cited as factors tempering the domestic outlook even as international growth remained robust.
Where it sits in the value chain
Intuitive Surgical sits in Stage 8 — Deployment & end markets, and it is this chain's single clearest example of what mature, monetised robot deployment actually looks like: a large installed base, a recurring-revenue business model built on ongoing use rather than one-time sale, and decades of accumulated evidence that the robots genuinely improve outcomes and workflow enough that customers keep paying for consumables procedure after procedure.
The comparison to Symbotic, this chain's other deployment-stage profile, is instructive: both companies prove that robots can generate genuine recurring revenue at scale, but through different mechanisms — Symbotic through warehouse automation systems and growing software/service attach, Intuitive through a medical-device consumables model that has had two decades longer to mature. Both stand in sharp contrast to the pre-revenue or early-revenue humanoid developers profiled across Stage 7 of this chain.
The bigger trend
Intuitive Surgical's business model is arguably the best available answer, in this entire chain, to the "what to watch" question raised repeatedly elsewhere: paid, repeated, productive work by a robot for a customer, generating recurring revenue tied to actual use. A da Vinci system doesn't get retired to an "internal training" fleet the way early Optimus and Atlas units currently are — it performs procedures for paying hospitals from day one, and the company's entire financial model depends on that use continuing and growing.
The relevance of Intuitive's model to humanoid robotics specifically is more about proving the destination than the path: a consumables-and-service recurring-revenue structure built around actual robot usage is the kind of business model humanoid developers eventually need to reach, even though a humanoid's hardware, applications and go-to-market are entirely different from a surgical robot's. Intuitive shows what it looks like when a robotics company gets there.
What to watch
- Full-year 2026 da Vinci procedure growth against the 13.5–15.5% guidance range, particularly whether U.S. moderation factors persist.
- da Vinci 5 adoption rate and utilisation improvement versus the prior-generation platform.
- Ion procedure growth, currently outpacing da Vinci growth and representing the company's newest major platform.
- International procedure growth sustainability across Europe, Asia and rest-of-world markets.
- China market developments specifically, given no clarity yet on new reimbursement charge codes expected before 2027.
Related companies
Also in this stage but not yet profiled: Novanta (Nasdaq: NOVT) and Tesla (Nasdaq: TSLA).
FAQ
How does Intuitive Surgical make most of its money?
Primarily from recurring instruments, accessories and service revenue tied to procedures performed on its installed base of da Vinci and Ion systems, rather than from selling new robots. Instruments and accessories revenue alone was $1.73 billion in Q2 2026, roughly 60% of total revenue, while system sales were $685 million.
How many da Vinci systems are in use worldwide?
As of June 30, 2026, the installed base reached 11,710 da Vinci systems, up 12% year over year, alongside 1,096 Ion endoluminal systems, up 21% year over year.
Is Intuitive Surgical profitable?
Yes, and highly so. Q2 2026 non-GAAP operating margin reached 42%, with GAAP net income of $818 million and non-GAAP net income of $1.00 billion on revenue of $2.89 billion, reflecting the high-margin economics of its recurring instruments and services revenue model.
Why is a surgical robot company included in a humanoid robot supply chain?
Intuitive Surgical represents the deployment stage of robotics — robots doing paid, productive work at scale, generating recurring revenue — that most humanoid developers profiled elsewhere in this chain are still working toward. It is included as a proof point of what a mature, monetised robotics deployment business actually looks like, not as a humanoid robot maker itself.